Partnership

UNC Chapel Hill x SAS Antiviral Drug Development Partnership

SAS and UNC Chapel Hill partnered to accelerate antiviral drug discovery through the Rapidly Emerging Antiviral Drug Development Initiative. SAS contributes AI and machine learning capabilities to advance drug discovery for future pandemic preparedness.

development · Active · verified

Track UNC Chapel Hill x SAS Antiviral Drug Development Partnership

Machine-readable surfaces

Markdown mirror: /partnerships/unc-chapel-hill-x-sas-antiviral-drug-development-partnership.md
JSON-LD: embedded in this page’s head
REST API: /v1/partnerships/unc-chapel-hill-x-sas-antiviral-drug-development-partnership
Revision history: /partnerships/unc-chapel-hill-x-sas-antiviral-drug-development-partnership/history
Data documentation: /data
Query this programmatically: Deploy MCP

aa6467ea-b81c-40c1-a4d8-bbdf5938f31b

Parties (2)

University of North Carolina at Chapel Hill co developer
SAS Institute off-registry technology provider

Sources (1)

https://uncnews.unc.edu/2021/09/14/sas-and-unc-chapel-hill-partner-to-accelerate-antiviral-drug-development/

Deploy Watch

Track this partnership.

We notify you when the status changes against primary-source evidence, expansion is verified, or the partnership is terminated.